Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers

Oligodendroglioma is characterized by unique clinical, pathological, and genetic features. Recurrent losses of chromosomes 1p and 19q are strongly associated with this brain cancer but knowledge of the identity and function of the genes affected by these alterations is limited. We performed exome sequencing on a discovery set of 16 oligodendrogliomas with 1p/19q co‐deletion to identify new molecular features at base‐pair resolution. As anticipated, there was a high rate of IDH mutations: all cases had mutations in either IDH1 (14/16) or IDH2 (2/16). In addition, we discovered somatic mutations and insertions/deletions in the CIC gene on chromosome 19q13.2 in 13/16 tumours. These discovery set mutations were validated by deep sequencing of 13 additional tumours, which revealed seven others with CIC mutations, thus bringing the overall mutation rate in oligodendrogliomas in this study to 20/29 (69%). In contrast, deep sequencing of astrocytomas and oligoastrocytomas without 1p/19q loss revealed that CIC alterations were otherwise rare (1/60; 2%). Of the 21 non‐synonymous somatic mutations in 20 CIC‐mutant oligodendrogliomas, nine were in exon 5 within an annotated DNA‐interacting domain and three were in exon 20 within an annotated protein‐interacting domain. The remaining nine were found in other exons and frequently included truncations. CIC mutations were highly associated with oligodendroglioma histology, 1p/19q co‐deletion, and IDH1/2 mutation (p < 0.001). Although we observed no differences in the clinical outcomes of CIC mutant versus wild‐type tumours, in a background of 1p/19q co‐deletion, hemizygous CIC mutations are likely important. We hypothesize that the mutant CIC on the single retained 19q allele is linked to the pathogenesis of oligodendrogliomas with IDH mutation. Our detailed study of genetic aberrations in oligodendroglioma suggests a functional interaction between CIC mutation, IDH1/2 mutation, and 1p/19q co‐deletion. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  Jean-Yves Delattre,et al.  Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile , 2008, Molecular Cancer.

[2]  Joel H. Saltz,et al.  The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas , 2010, PloS one.

[3]  K. Aldape,et al.  International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. , 2011, Neuro-oncology.

[4]  H. Aburatani,et al.  Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. , 2006, Human molecular genetics.

[5]  Wai-In Chan,et al.  CIC, a member of a novel subfamily of the HMG-box superfamily, is transiently expressed in developing granule neurons. , 2002, Brain research. Molecular brain research.

[6]  Wai-In Chan,et al.  CIC, a gene involved in cerebellar development and ErbB signaling, is significantly expressed in medulloblastomas , 2005, Journal of Neuro-Oncology.

[7]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[8]  N. Probst-Hensch,et al.  Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas , 2004, Acta Neuropathologica.

[9]  S. Weiss,et al.  Oligodendroglioma cell lines containing t(1;19)(q10;p10). , 2010, Neuro-oncology.

[10]  Steven J. M. Jones,et al.  Using next‐generation sequencing for the diagnosis of rare disorders: a family with retinitis pigmentosa and skeletal abnormalities , 2011, The Journal of pathology.

[11]  Amar Gajjar,et al.  Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.

[12]  Steven J. M. Jones,et al.  Abyss: a Parallel Assembler for Short Read Sequence Data Material Supplemental Open Access , 2022 .

[13]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[14]  G. Reifenberger,et al.  Loss of NOTCH2 Positively Predicts Survival in Subgroups of Human Glial Brain Tumors , 2007, PloS one.

[15]  Janghoo Lim,et al.  ATAXIN-1 Interacts with the Repressor Capicua in Its Native Complex to Cause SCA1 Neuropathology , 2006, Cell.

[16]  Barry Merriman,et al.  U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell Line , 2010, PLoS genetics.

[17]  Pieter Wesseling,et al.  IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group , 2010, Clinical Cancer Research.

[18]  Ryan D. Morin,et al.  Mutation of FOXL2 in granulosa-cell tumors of the ovary. , 2009, The New England journal of medicine.

[19]  Stephen Yip,et al.  MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance , 2009, Clinical Cancer Research.

[20]  Vladimir N Uversky,et al.  Oncogenic Partnerships: EWS-FLI1 Protein Interactions Initiate Key Pathways of Ewing's Sarcoma , 2010, Clinical Cancer Research.

[21]  Cynthia Hawkins,et al.  Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.

[22]  D J Goff,et al.  Establishment of dorsal-ventral polarity of the Drosophila egg requires capicua action in ovarian follicle cells. , 2001, Development.

[23]  M. Shago,et al.  Detailed cytogenetic and array analysis of pediatric primitive sarcomas reveals a recurrent CIC-DUX4 fusion gene event. , 2009, Cancer genetics and cytogenetics.

[24]  Caterina Giannini,et al.  The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors , 2005, Cancer.

[25]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[26]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[27]  S. Kesari,et al.  Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. , 2010, Genes & cancer.

[28]  D. Louis WHO classification of tumours of the central nervous system , 2007 .

[29]  B. Scheithauer,et al.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.

[30]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[31]  G. Jiménez,et al.  Relief of gene repression by torso RTK signaling: role of capicua in Drosophila terminal and dorsoventral patterning. , 2000, Genes & development.

[32]  Jianjie Ma,et al.  Ataxin‐1 and Brother of ataxin‐1 are components of the Notch signalling pathway , 2011, EMBO reports.

[33]  C. Brennan,et al.  Molecular subclassification of diffuse gliomas: Seeing order in the chaos , 2011, Glia.

[34]  S. Pulst,et al.  dAtaxin-2 Mediates Expanded Ataxin-1-Induced Neurodegeneration in a Drosophila Model of SCA1 , 2007, PLoS genetics.

[35]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[36]  Yuchen Jiao,et al.  Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma , 2011, Science.

[37]  C. Hoogenraad,et al.  Segregation of non‐p.R132H mutations in IDH1 in distinct molecular subtypes of glioma , 2010, Human mutation.

[38]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[39]  D. Louis,et al.  Chemosensitive gliomas in adults: which ones and why? , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[41]  K. Hoang-Xuan,et al.  NOTCH2 Is Neither Rearranged nor Mutated in t(1;19) Positive Oligodendrogliomas , 2009, PloS one.

[42]  Kevin P. Murphy,et al.  SNVMix: predicting single nucleotide variants from next-generation sequencing of tumors , 2010, Bioinform..

[43]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[44]  Steven J. M. Jones,et al.  De novo assembly and analysis of RNA-seq data , 2010, Nature Methods.

[45]  Steven J. M. Jones,et al.  MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers , 2011, Nature.

[46]  F. Dasí,et al.  Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression , 2009, Journal of Neuro-Oncology.

[47]  M. Nikiforova,et al.  Diagnostic Use of IDH1/2 Mutation Analysis in Routine Clinical Testing of Formalin-Fixed, Paraffin-Embedded Glioma Tissues , 2009, Journal of neuropathology and experimental neurology.

[48]  Andrew P. Stubbs,et al.  Absence of Common Somatic Alterations in Genes on 1p and 19q in Oligodendrogliomas , 2011, PloS one.

[49]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.

[50]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[51]  Inanç Birol,et al.  Human variation database: an open-source database template for genomic discovery , 2011, Bioinform..

[52]  I. Hariharan,et al.  Capicua Regulates Cell Proliferation Downstream of the Receptor Tyrosine Kinase/Ras Signaling Pathway , 2007, Current Biology.

[53]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[54]  Tracy T Batchelor,et al.  A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.